These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29300712)

  • 1. Response to the Letter to the Editor "Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?" by Neoptolemos and Colleagues.
    Hackert T; Michalski CW; Büchler MW
    Ann Surg; 2018 Feb; 267(2):e36-e37. PubMed ID: 29300712
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?
    Neoptolemos JP; Halloran CM; Ghaneh P; Kleeff J
    Ann Surg; 2018 Feb; 267(2):e35-e36. PubMed ID: 29300711
    [No Abstract]   [Full Text] [Related]  

  • 3. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
    J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
    Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S
    J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX.
    Hu HJ; Li FY
    Ann Surg; 2018 Dec; 268(6):e95-e96. PubMed ID: 29864093
    [No Abstract]   [Full Text] [Related]  

  • 7. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX: from the ACCORD study to 2014.
    Oikonomopoulos GM; Syrigos KN; Skoura E; Saif MW
    JOP; 2014 Mar; 15(2):103-5. PubMed ID: 24618428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. Reply.
    Malka D; Castan F; Conroy T
    N Engl J Med; 2019 Mar; 380(12):1188-1189. PubMed ID: 30893544
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant therapy for localized pancreatic cancer: support is growing?
    Evans DB; Ritch PS; Erickson BA
    Ann Surg; 2015 Jan; 261(1):18-20. PubMed ID: 25599323
    [No Abstract]   [Full Text] [Related]  

  • 13. Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
    Jones TS; Jones EL; McManus M; Shah R; Gajdos C
    JOP; 2013 May; 14(3):289-91. PubMed ID: 23669483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
    Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
    Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].
    Strobel O; Büchler MW
    Chirurg; 2015 Feb; 86(2):183. PubMed ID: 25673227
    [No Abstract]   [Full Text] [Related]  

  • 16. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
    Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
    J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
    Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
    Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
    Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
    Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.